Cargando…

Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study

Galectin-3 (Gal-3) is a new independent risk factor in the development and severity of coronary artery disease (CAD). The aim of the study was to evaluate whether Gal-3 concentration has prognostic value and if it reflects the progression of atherosclerosis in carotid arteries in patients with CAD a...

Descripción completa

Detalles Bibliográficos
Autores principales: Święcki, Przemysław, Sawicki, Robert, Knapp, Małgorzata, Kamiński, Karol Adam, Ptaszyńska-Kopczyńska, Katarzyna, Sobkowicz, Bożena, Lisowska, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355423/
https://www.ncbi.nlm.nih.gov/pubmed/32485853
http://dx.doi.org/10.3390/jcm9061640
_version_ 1783558271848677376
author Święcki, Przemysław
Sawicki, Robert
Knapp, Małgorzata
Kamiński, Karol Adam
Ptaszyńska-Kopczyńska, Katarzyna
Sobkowicz, Bożena
Lisowska, Anna
author_facet Święcki, Przemysław
Sawicki, Robert
Knapp, Małgorzata
Kamiński, Karol Adam
Ptaszyńska-Kopczyńska, Katarzyna
Sobkowicz, Bożena
Lisowska, Anna
author_sort Święcki, Przemysław
collection PubMed
description Galectin-3 (Gal-3) is a new independent risk factor in the development and severity of coronary artery disease (CAD). The aim of the study was to evaluate whether Gal-3 concentration has prognostic value and if it reflects the progression of atherosclerosis in carotid arteries in patients with CAD after acute myocardial infarction (AMI). The analysis included 110 patients who were hospitalized due to AMI, treated with primary coronary intervention (PCI) and further attended a follow-up visit, and 100 healthy volunteers. The Gal-3 concentration and carotid ultrasound were evaluated at baseline and on a follow-up visit. We found that the Gal-3 concentration in the group with hyperlipidemia decreased during the observation (10.7 vs. 7.9 ng/mL, p = 0.00003). Patients rehospitalized during follow up had higher concentration of Gal-3 in the acute phase of myocardial infarction (MI) (10.7 vs. 7.2 ng/mL, p = 0.02; 10.1 vs. 8.0 ng/mL, p = 0.002, respectively). In the group of patients who had none of the following endpoints: subsequent MI, PCI, coronary artery bypass grafting (CABG) or stroke, there was a decrease in Gal-3 concentration at the follow-up visit. Parameters affecting the frequency of a composite endpoint occurrence are: the presence of atheromatous plaque in the carotid artery (p = 0.017), Gal-3 (p = 0.004) and haemoglobin (p = 0.03) concentration. In multivariate analysis, only Gal-3 concentration higher than 9.2 ng/mL at discharge was associated with a nine-fold increase of risk of composite endpoint occurrence (p = 0.0005, OR = 9.47, 95% CI 2.60–34.45). A significant decrease in Gal-3 concentration was observed in the group of patients after AMI without the endpoint occurrence during observation.
format Online
Article
Text
id pubmed-7355423
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73554232020-07-23 Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study Święcki, Przemysław Sawicki, Robert Knapp, Małgorzata Kamiński, Karol Adam Ptaszyńska-Kopczyńska, Katarzyna Sobkowicz, Bożena Lisowska, Anna J Clin Med Article Galectin-3 (Gal-3) is a new independent risk factor in the development and severity of coronary artery disease (CAD). The aim of the study was to evaluate whether Gal-3 concentration has prognostic value and if it reflects the progression of atherosclerosis in carotid arteries in patients with CAD after acute myocardial infarction (AMI). The analysis included 110 patients who were hospitalized due to AMI, treated with primary coronary intervention (PCI) and further attended a follow-up visit, and 100 healthy volunteers. The Gal-3 concentration and carotid ultrasound were evaluated at baseline and on a follow-up visit. We found that the Gal-3 concentration in the group with hyperlipidemia decreased during the observation (10.7 vs. 7.9 ng/mL, p = 0.00003). Patients rehospitalized during follow up had higher concentration of Gal-3 in the acute phase of myocardial infarction (MI) (10.7 vs. 7.2 ng/mL, p = 0.02; 10.1 vs. 8.0 ng/mL, p = 0.002, respectively). In the group of patients who had none of the following endpoints: subsequent MI, PCI, coronary artery bypass grafting (CABG) or stroke, there was a decrease in Gal-3 concentration at the follow-up visit. Parameters affecting the frequency of a composite endpoint occurrence are: the presence of atheromatous plaque in the carotid artery (p = 0.017), Gal-3 (p = 0.004) and haemoglobin (p = 0.03) concentration. In multivariate analysis, only Gal-3 concentration higher than 9.2 ng/mL at discharge was associated with a nine-fold increase of risk of composite endpoint occurrence (p = 0.0005, OR = 9.47, 95% CI 2.60–34.45). A significant decrease in Gal-3 concentration was observed in the group of patients after AMI without the endpoint occurrence during observation. MDPI 2020-05-29 /pmc/articles/PMC7355423/ /pubmed/32485853 http://dx.doi.org/10.3390/jcm9061640 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Święcki, Przemysław
Sawicki, Robert
Knapp, Małgorzata
Kamiński, Karol Adam
Ptaszyńska-Kopczyńska, Katarzyna
Sobkowicz, Bożena
Lisowska, Anna
Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study
title Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study
title_full Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study
title_fullStr Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study
title_full_unstemmed Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study
title_short Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study
title_sort galectin-3 as the prognostic factor of adverse cardiovascular events in long-term follow up in patients after myocardial infarction—a pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355423/
https://www.ncbi.nlm.nih.gov/pubmed/32485853
http://dx.doi.org/10.3390/jcm9061640
work_keys_str_mv AT swieckiprzemysław galectin3astheprognosticfactorofadversecardiovasculareventsinlongtermfollowupinpatientsaftermyocardialinfarctionapilotstudy
AT sawickirobert galectin3astheprognosticfactorofadversecardiovasculareventsinlongtermfollowupinpatientsaftermyocardialinfarctionapilotstudy
AT knappmałgorzata galectin3astheprognosticfactorofadversecardiovasculareventsinlongtermfollowupinpatientsaftermyocardialinfarctionapilotstudy
AT kaminskikaroladam galectin3astheprognosticfactorofadversecardiovasculareventsinlongtermfollowupinpatientsaftermyocardialinfarctionapilotstudy
AT ptaszynskakopczynskakatarzyna galectin3astheprognosticfactorofadversecardiovasculareventsinlongtermfollowupinpatientsaftermyocardialinfarctionapilotstudy
AT sobkowiczbozena galectin3astheprognosticfactorofadversecardiovasculareventsinlongtermfollowupinpatientsaftermyocardialinfarctionapilotstudy
AT lisowskaanna galectin3astheprognosticfactorofadversecardiovasculareventsinlongtermfollowupinpatientsaftermyocardialinfarctionapilotstudy